Clinical Challenges: Implementing More Guideline-Endorsed SGLT2i Use New strategies needed to ensure all are on board with fourth pillar of HF treatment Apr 11, 2022
Two PCI Guidance Strategies on Par for Intermediate Coronary Stenosis FLAVOUR trial weighs in on FFR versus IVUS Apr 05, 2022
Which Drug-Coated Balloon Proved Superior in Peripheral Artery Disease? Second-generation device goes head-to-head with popular first-gen device Apr 05, 2022
Study Provides 'Elusive' Link Between Kids' Health and Adult Heart Events CV risk factors in childhood tied to midlife CV events and CVD Apr 05, 2022
Transcatheter Tricuspid Repair Shows Early Promise PASCAL device safe and linked to symptom improvement in severe tricuspid regurgitation Apr 04, 2022
Higher-Dose ANGPTL3 Inhibitor Cuts Lipids but With Questionable Safety Significant safety signals in dose-ranging trial may end drug's future in CV prevention Apr 03, 2022
Tranexamic Acid Cuts Surgical Bleeding in Yet Another Setting But POISE-3 trial leaves open the question of cardiovascular safety Apr 02, 2022
From 'Pre-HF' to 'HFimpEF': Guidelines Redefine Heart Failure Stages, Classes Update also adds SGLT2 inhibitor as a pillar of therapy Apr 01, 2022
Cardiomyopathy: Epidemiology, Etiology, and Pathophysiology A brief guide through the wide range of cardiomyopathies Apr 01, 2022
For Your Patients: How to Prepare for Your Cardiomyopathy Appointment Questions to ask your cardiologist, and answers you might need Apr 01, 2022